ALZHEIMERS DISEASE RESEARCH FOUNDATION: Form 990, tax year 2025

View the entire original 990 at ProPublica ↗

Organization: ALZHEIMERS DISEASE RESEARCH FOUNDATION (EIN 52-2396428)
Tax period: 2025-01-01 to 2025-12-31
Filed: 2026-05-11
IRS object ID: 202641319349301469
Schema version: 2025v4.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2026-05-11T09:00:52-05:00	ReturnTs
Tax Period End	2025-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	050409384	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KAHN LITWIN RENZA & CO LTD	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	951 NORTH MAIN STREET	AddressLine1Txt
City	PROVIDENCE	CityNm
State Abbreviation	RI	StateAbbreviationCd
ZIP	02904	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2025-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	522396428	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	ALZHEIMER'S DISEASE RESEARCH FOUNDATION	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	ALZH	BusinessNameControlTxt
Phone	7812373800	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	34 WASHINGTON ST 230	AddressLine1Txt
City	WELLESLEY HILLS	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	02481	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MARGARET E SMITH	PersonNm
Person Title	CEO & DIRECTOR	PersonTitleTxt
Phone	7812373800	PhoneNum
Signature	2026-05-11	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	SANDY ROSS	PreparerPersonNm
PTIN	P01399337	PTIN
Phone	4012742001	PhoneNum
Preparation	2026-05-08	PreparationDt

Field	Value	IRS element (for citing)
Tax	2025	TaxYr
Build TS	2025-03-06 01:10:19Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	CURE ALZHEIMER'S FUND	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Principal Officer	MARGARET E SMITH	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	34 WASHINGTON ST 230	AddressLine1Txt
City	WELLESLEY HILLS	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	02481	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$62,464,569	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	HTTP://CUREALZ.ORG/	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2004	FormationYr
Legal Domicile State	PA	LegalDomicileStateCd
Activity Or Mission	TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE.	ActivityOrMissionDesc
Voting Members Governing Body	11	VotingMembersGoverningBodyCnt
Voting Members Independent	10	VotingMembersIndependentCnt
Total Employee	38	TotalEmployeeCnt
Total Volunteers	100	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$30,788,755	PYContributionsGrantsAmt
CY Contributions Grants	$55,333,840	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$964,653	PYInvestmentIncomeAmt
CY Investment Income	$1,312,647	CYInvestmentIncomeAmt
PY Other Revenue	$2,269	PYOtherRevenueAmt
CY Other Revenue	$13,348	CYOtherRevenueAmt
PY Total Revenue	$31,755,677	PYTotalRevenueAmt
CY Total Revenue	$56,659,835	CYTotalRevenueAmt
PY Grants And Similar Paid	$28,828,950	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$37,323,497	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$5,244,116	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$5,904,594	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$2,357,449	CYTotalFundraisingExpenseAmt
PY Other Expenses	$2,926,002	PYOtherExpensesAmt
CY Other Expenses	$3,004,585	CYOtherExpensesAmt
PY Total Expenses	$36,999,068	PYTotalExpensesAmt
CY Total Expenses	$46,232,676	CYTotalExpensesAmt
PY Revenues Less Expenses	-$5,243,391	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$10,427,159	CYRevenuesLessExpensesAmt
Total Assets BOY	$28,586,231	TotalAssetsBOYAmt
Total Assets EOY	$43,169,584	TotalAssetsEOYAmt
Total Liabilities BOY	$1,722,043	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$6,057,359	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$26,864,188	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$37,112,225	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. ALL OVERHEAD EXPENSES ARE PAID BY THE BOARD OF DIRECTORS, TRUSTEES AND CORE GROUP OF OTHER DONORS, ALLOWING 100% OF GENERAL DONATIONS TO FUND OUR RESEARCH PROGRAMS.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$38,338,893	ExpenseAmt
Grant	$37,323,497	GrantAmt
Desc	IN 2025, CURE ALZHEIMER'S FUND SUPPORTED 161 RESEARCH PROJECTS AT 74 LEADING RESEARCH INSTITUTIONS, FOR A TOTAL RESEARCH OUTPUT OF $38.3 MILLION. PROJECTS IDENTIFIED AND INVESTIGATED MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE AS POTENTIAL THERAPEUTIC TARGETS. OTHER STANDALONE PROJECTS AND MULTI-LAB CONSORTIA PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF NEUROINFLAMMATION, THE GUT MICROBIOME, AND THE IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. CUREALZ ALSO PROVIDED FUNDING TO SUSTAIN VITAL RESEARCH ASSETS, LIKE BRAIN BANKS AND SCIENTIFIC TRAINEES, FACING UNANTICIPATED REDUCTIONS IN FEDERAL SUPPORT. ADDITIONAL EXPENSES INCLUDE SCIENTIFIC MEETING HOSTING; HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$4,220,285	ExpenseAmt
Desc	CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, WEBINARS, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED FOR MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$42,559,178	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	0	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	0	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	Yes (1)	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	41	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Employee	38	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (1)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (1)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	11	GoverningBodyVotingMembersCnt
Independent Voting Member	10	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Other Website	Yes (X)	OtherWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	MARGARET E SMITH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	7812373800	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	34 WASHINGTON STREET STE 230	AddressLine1Txt
City	WELLESLEY HILLS	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	02481	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (20 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
MARGARET E SMITH
CEO & DIRECTOR	40.00	Yes (X)	Yes (X)	$501,560	$0	$29,619
HENRY MCCANCE
CHAIR & DIRECTOR	5.00	Yes (X)	Yes (X)	$0	$0	$0
PHYLLIS RAPPAPORT
TREASURER & DIRECTOR	5.00	Yes (X)	Yes (X)	$0	$0	$0
TIMOTHY ARMOUR
DIRECTOR	3.00	Yes (X)		$0	$0	$0
RICHARD BIRNBAUM
DIRECTOR	4.00	Yes (X)		$0	$0	$0
BRITTANY BOWLEN
DIRECTOR (AS OF 5/25)	3.00	Yes (X)		$0	$0	$0
MARK FAGGIANO
DIRECTOR	3.00	Yes (X)		$0	$0	$0
MARY GREENHILL CAGLIERO
DIRECTOR	3.00	Yes (X)		$0	$0	$0
KUMAR MAHADEVA
DIRECTOR	3.00	Yes (X)		$0	$0	$0
JACQUELINE MORBY
DIRECTOR	4.00	Yes (X)		$0	$0	$0
CHRISTINE VILLAS-BOAS
DIRECTOR (AS OF 3/25)	3.00	Yes (X)		$0	$0	$0
JOSEPHINE ANTONELLIS
CFO	30.00		Yes (X)	$225,192	$0	$8,002
LAUREL LYLE
SECRETARY & VP, BOARD RELATIONS & DEV.	30.00		Yes (X)	$133,686	$0	$4,655
KATHARINE HERMAN
EVP DEVELOPMENT	40.00			$458,522	$0	$31,035	Yes (X)
BARBARA CHAMBERS
EVP MARKETING & COMM.	40.00			$303,031	$0	$24,478	Yes (X)
DANIEL HARPER
VP DEVELOPMENT	40.00			$220,918	$0	$14,361		Yes (X)
LISA RAND
VP MARKETING & COMM.	40.00			$217,091	$0	$19,494		Yes (X)
JOHN SLATTERY
SVP, PHILANTHROPIC PARTNERSHIPS	40.00			$213,548	$0	$7,462		Yes (X)
MAHUA DASGUPTA
SR. PHILANTROPIC ADVISOR	40.00			$193,723	$0	$26,754		Yes (X)
THIDAPHORN SENGSAVANH
DIRECTOR OF DEVELOPMENT OPERATIONS	40.00			$170,896	$0	$25,682		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$2,638,167	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$191,542	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	19	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp

Contractor Name ContractorName

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PROPER VILLAINS LLC	BusinessNameLine1Txt

Contractor Address ContractorAddress

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	855 BOYLSTON STREET 10TH FLOOR	AddressLine1Txt
City	BOSTON	CityNm
State Abbreviation	MA	StateAbbreviationCd
ZIP	02116	ZIPCd

Field	Value	IRS element (for citing)
Services	CREATIVE AND PRODUCTION SERVICES	ServicesDesc
Compensation	$130,663	CompensationAmt

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	1	CntrctRcvdGreaterThan100KCnt
Fundraising	$321,940	FundraisingAmt
All Other Contributions	$55,011,900	AllOtherContributionsAmt
Noncash Contributions	$5,675,241	NoncashContributionsAmt
Total Contributions	$55,333,840	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,334,483	TotalRevenueColumnAmt
Exclusion	$1,334,483	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$5,687,546	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$5,709,382	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	-$21,836	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$21,836	TotalRevenueColumnAmt
Exclusion	-$21,836	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$108,700	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$321,940	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$95,352	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$13,348	TotalRevenueColumnAmt
Exclusion	$13,348	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$56,659,835	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$1,325,995	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$33,812,354	TotalAmt
Program Services	$33,812,354	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$3,511,143	TotalAmt
Program Services	$3,511,143	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$1,719,780	TotalAmt
Program Services	$929,771	ProgramServicesAmt
Management And General	$412,287	ManagementAndGeneralAmt
Fundraising	$377,722	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$3,414,234	TotalAmt
Program Services	$1,994,996	ProgramServicesAmt
Management And General	$454,082	ManagementAndGeneralAmt
Fundraising	$965,156	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$80,940	TotalAmt
Program Services	$50,437	ProgramServicesAmt
Management And General	$8,766	ManagementAndGeneralAmt
Fundraising	$21,737	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$336,158	TotalAmt
Program Services	$193,636	ProgramServicesAmt
Management And General	$55,697	ManagementAndGeneralAmt
Fundraising	$86,825	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$353,482	TotalAmt
Program Services	$199,198	ProgramServicesAmt
Management And General	$60,093	ManagementAndGeneralAmt
Fundraising	$94,191	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$105,987	TotalAmt
Program Services	$963	ProgramServicesAmt
Management And General	$18,560	ManagementAndGeneralAmt
Fundraising	$86,464	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$40,676	TotalAmt
Management And General	$40,676	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$53,906	TotalAmt
Management And General	$53,906	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$597,442	TotalAmt
Program Services	$322,780	ProgramServicesAmt
Management And General	$48,011	ManagementAndGeneralAmt
Fundraising	$226,651	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$811,566	TotalAmt
Program Services	$811,566	ProgramServicesAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$180,267	TotalAmt
Program Services	$108,285	ProgramServicesAmt
Management And General	$26,885	ManagementAndGeneralAmt
Fundraising	$45,097	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$176,806	TotalAmt
Program Services	$77,747	ProgramServicesAmt
Management And General	$72,554	ManagementAndGeneralAmt
Fundraising	$26,505	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$96,980	TotalAmt
Program Services	$56,117	ProgramServicesAmt
Management And General	$15,933	ManagementAndGeneralAmt
Fundraising	$24,930	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$133,968	TotalAmt
Program Services	$56,599	ProgramServicesAmt
Management And General	$1,110	ManagementAndGeneralAmt
Fundraising	$76,259	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$349,673	TotalAmt
Program Services	$299,741	ProgramServicesAmt
Management And General	$18,702	ManagementAndGeneralAmt
Fundraising	$31,230	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$2,896	TotalAmt
Program Services	$744	ProgramServicesAmt
Management And General	$476	ManagementAndGeneralAmt
Fundraising	$1,676	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$28,809	TotalAmt
Program Services	$5,267	ProgramServicesAmt
Management And General	$21,202	ManagementAndGeneralAmt
Fundraising	$2,340	FundraisingAmt

Other Expenses OtherExpensesGrp (3 entries)

DescDesc	TotalTotalAmt	FundraisingFundraisingAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt
GIFT PROCESSING FEES	$266,060	$266,060
RESEARCH LAB EXPENSES	$86,974		$86,974
MISCELLANEOUS	$72,575	$24,606	$40,860	$7,109

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$46,232,676	TotalAmt
Program Services	$42,559,178	ProgramServicesAmt
Management And General	$1,316,049	ManagementAndGeneralAmt
Fundraising	$2,357,449	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$2,815,537	BOYAmt
EOY	$3,565,286	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$322,954	BOYAmt
EOY	$1,802,130	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$1,707,733	BOYAmt
EOY	$9,622,053	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$246,040	BOYAmt
EOY	$321,471	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$8,688	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$3,620	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$7,964	BOYAmt
EOY	$5,068	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$23,255,145	BOYAmt
EOY	$27,704,096	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$230,858	BOYAmt
EOY	$149,480	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$28,586,231	BOYAmt
EOY	$43,169,584	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$167,083	BOYAmt
EOY	$363,629	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$600,901	BOYAmt
EOY	$4,812,010	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$954,059	BOYAmt
EOY	$881,720	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,722,043	BOYAmt
EOY	$6,057,359	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$25,165,313	BOYAmt
EOY	$26,004,933	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$1,698,875	BOYAmt
EOY	$11,107,292	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$26,864,188	BOYAmt
EOY	$37,112,225	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$28,586,231	BOYAmt
EOY	$43,169,584	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$10,427,159	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$179,122	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	0	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$26,547,838	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$32,354,655	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$36,697,205	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$30,788,755	CurrentTaxYearMinus1YearAmt
Current Tax Year	$55,362,142	CurrentTaxYearAmt
Total	$181,750,595	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$26,547,838	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$32,354,655	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$36,697,205	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$30,788,755	CurrentTaxYearMinus1YearAmt
Current Tax Year	$55,362,142	CurrentTaxYearAmt
Total	$181,750,595	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$14,368,215	SubstantialContributorsTotAmt
Public Support Total170	$167,382,380	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$4,497	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$93,408	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$992,260	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$997,714	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,334,483	CurrentTaxYearAmt
Total	$3,422,362	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$185,172,957	TotalSupportAmt
Gross Receipts Rltd Activities	$397,698	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.90390	PublicSupportCY170Pct
Public Support PY170	0.86450	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$8,688	OtherCostOrOtherBasisAmt
Depreciation	$3,620	DepreciationAmt
Book Value	$5,068	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$5,068	TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
ACCRUED PAYROLL AND RELATED	$739,590
LEASE PAYABLE	$142,130

Field	Value	IRS element (for citing)
Total Liability	$881,720	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$56,426,807	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	-$179,122	NetUnrealizedGainsInvstAmt
Revenue Not Reported	-$179,122	RevenueNotReportedAmt
Revenue Subtotal	$56,605,929	RevenueSubtotalAmt
Investment Expenses Not Incld	$53,906	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$53,906	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$56,659,835	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$46,178,770	TotExpnsEtcAuditedFinclStmtAmt
Expenses Not Reported	$0	ExpensesNotReportedAmt
Expenses Subtotal	$46,178,770	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$53,906	InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt	$53,906	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$46,232,676	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART X, LINE 2:	FormAndLineReferenceDesc
Explanation	THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS.	ExplanationTxt

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND) - BELGIUM, FINLAND, GERMANY, NETHERL	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	$2,488,952
MIDDLE EAST AND NORTH AFRICA - ISRAEL	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	$7,763
EAST ASIA AND THE PACIFIC - AUSTRALIA, SINGAPORE	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	$402,388
NORTH AMERICA - CANADA	GRANTS AWARDED	ALZHEIMER'S DISEASE RESEARCH	$612,041

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$3,511,144	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$3,511,144	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (25 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
AUSTRALIA	DEVELOPING BRAIN-TARGETED AAVS USING HUMAN BLOOD-BRAIN BARRIER RECEPTORS	$201,138	WIRE TRANSFER	$0
BELGIUM	BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE	$166,750	WIRE TRANSFER	$0
BELGIUM	PRECLINICAL ANALYSIS OF SYNAPTOGYRIN-3 OLIGONUCLEOTIDES TO TARGET TAUOPATHY	$201,250	WIRE TRANSFER	$0
BELGIUM	BAC: THE 100-PLUS STUDY BRAIN COHORT: IDENTIFYING MOLECULAR DETERMINANTS OF RESISTANCE, RESILIENCE AND EARLY COGNITIVE DECLINE IN THE OLDEST-OLD	$287,500	WIRE TRANSFER	$0
CANADA	UNRAVELLING PRECISION HORMONE THERAPY USING MENOPAUSE AND HORMONE THERAPY TYPE ACROSS APOE GENOTYPE	$201,250	WIRE TRANSFER	$0
CANADA	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	$7,763	WIRE TRANSFER	$0
CANADA	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	$47,115	WIRE TRANSFER	$0
CANADA	REFERENCE INTERVALS FOR PLASMA P-TAU-217 IN THE CANADIAN POPULATION	$57,500	WIRE TRANSFER	$0
CANADA	APOE CONSORTIUM: APOE AND IMMUNE CHECKPOINT REGULATION DURING AGING	$298,414	WIRE TRANSFER	$0
FINLAND	NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE	$23,000	WIRE TRANSFER	$0
GERMANY	CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE	$111,780	WIRE TRANSFER	$0
GERMANY	CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE	$34,500	WIRE TRANSFER	$0
ISRAEL	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER	$7,763	WIRE TRANSFER	$0
NETHERLANDS	UNDERSTANDING THE DYNAMIC LIPID-IMMUNOMETABOLOME OF PROTECTIVE AND RISK ALZHEIMER MICROGLIA	$201,250	WIRE TRANSFER	$0
NORWAY	ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE	$108,000	WIRE TRANSFER	$0
SINGAPORE	MULTIDIMENSIONAL PROFILING OF TREM2-MUTATED OR APOE4-MUTATED MICROGLIA IN HUMAN BRAIN ORGANOIDS TO UNDERSTAND DYSREGULATED MICROGLIA NEURONAL CROSSTALK IN AD	$201,250	WIRE TRANSFER	$0
SWEDEN	ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE	$90,620	WIRE TRANSFER	$0
SWEDEN	CHARACTERIZATION OF TAU PATHOLOGY HETEROGENEITY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM	$201,250	WIRE TRANSFER	$0
SWEDEN	UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP)	$84,004	WIRE TRANSFER	$0
UNITED KINGDOM	BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE	$33,638	WIRE TRANSFER	$0
UNITED KINGDOM	SCALING THE DIVIDE IN ALZHEIMER'S DISEASE: AN INTEGRATED MOLECULAR, CELLULAR AND NETWORK-LEVEL STUDY	$201,199	WIRE TRANSFER	$0
UNITED KINGDOM	USING LONG-READ SEQUENCING TO INVESTIGATE THE MAPT LOCUS AND TRANSCRIPTS IN NEURODEGENERATION	$201,250	WIRE TRANSFER	$0
UNITED KINGDOM	CELLULAR VULNERABILITY TO PATHOLOGICAL TAU PROTEIN ACCUMULATION IN ALZHEIMER'S DISEASE	$229,770	WIRE TRANSFER	$0
UNITED KINGDOM	INVESTIGATING THE SERIAL PATHOLOGIES RELATED TO PLASMA BIOMARKERS IN NLFTAUM/H MICE; A NEW MOUSE MODEL FEATURING NEUROFIBRILLARY TANGLES AS A RESULT OF RISING AMYLOID WITHOUT MAPT MUTATIONS	$197,083	WIRE TRANSFER	$0
UNITED KINGDOM	UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP)	$116,107	WIRE TRANSFER	$0

Field	Value	IRS element (for citing)
Total501c3 Org	19	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED.	ExplanationTxt

Schedule G IRS990ScheduleG

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	FISHER ISLAND GOLF	Event1Nm
Gross Receipts Event1	$430,640	GrossReceiptsEvent1Amt
Charitable Contri Event1	$321,940	CharitableContriEvent1Amt
Gross Revenue Event1	$108,700	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$62,400	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$7,664	FoodAndBeverageEvent1Amt
Other Direct Expenses Event1	$25,288	OtherDirectExpensesEvent1Amt
Gross Receipts Total	$430,640	GrossReceiptsTotalAmt
Charitable Contributions Tot	$321,940	CharitableContributionsTotAmt
Gross Revenue Total Events	$108,700	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$62,400	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$7,664	FoodAndBeverageTotalEventsAmt
Oth Direct Expnss Total Events	$25,288	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$95,352	DirectExpenseSummaryEventsAmt
Net Income Summary	$13,348	NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (161 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
1120 15TH STREET CJ3301	AUGUSTA	GA	30912	581418202	501 (C)(3)	$201,250	$0	THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY
BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZA	HOUSTON	TX	77030	741613878	501 (C)(3)	$138,000	$0	DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE
BETH ISRAEL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUE	BOSTON	MA	02215	042103881	501 (C)(3)	$201,250	$0	INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE
BOSTON CHILDREN'S HOSPITAL
300 LONGWOOD AVE	BOSTON	MA	02215	042774441	501 (C)(3)	$264,500	$0	BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT)
BOSTON CHILDREN'S HOSPITAL
300 LONGWOOD AVE	BOSTON	MA	02215	042774441	501 (C)(3)	$57,500	$0	TRACKING INFLAMMATION AND REPAIR AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE
BOSTON CHILDREN'S HOSPITAL
300 LONGWOOD AVE	BOSTON	MA	02215	042774441	501 (C)(3)	$344,528	$0	NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE
BOSTON CHILDREN'S HOSPITAL
300 LONGWOOD AVE	BOSTON	MA	02215	042774441	501 (C)(3)	$80,500	$0	HOW BODY-BRAIN INFLAMMATORY SIGNALS VIA BORDER MACROPHAGES ALTER THE NEUROIMMUNE LANDSCAPE AND DRIVE ALZHEIMER'S PATHOLOGY
BRIGHAM AND WOMEN'S HOSPITAL
75 FRANCIS STREET	BOSTON	MA	02215	042312909	501 (C)(3)	$575,000	$0	APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS
BRIGHAM AND WOMEN'S HOSPITAL
75 FRANCIS STREET	BOSTON	MA	02215	042312909	501 (C)(3)	$431,250	$0	A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE
BRIGHAM AND WOMEN'S HOSPITAL
75 FRANCIS STREET	BOSTON	MA	02215	042312909	501 (C)(3)	$201,250	$0	VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN
BRIGHAM AND WOMEN'S HOSPITAL
75 FRANCIS STREET	BOSTON	MA	02215	042312909	501 (C)(3)	$228,900	$0	DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA?
BRIGHAM AND WOMEN'S HOSPITAL
75 FRANCIS STREET	BOSTON	MA	02215	042312909	501 (C)(3)	$201,234	$0	T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE
BURKE NEUROLOGICAL INSTITUTE
785 MAMARONECK AVE	WHITE PLAINS	NY	106052523	133434924	501 (C)(3)	$173,007	$0	2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE
CARNEGIE MELLON UNIVERSITY
5000 FORBES AVE	PITTSBURGH	PA	15213	250969449	501 (C)(3)	$201,250	$0	INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS
COLUMBIA UNIVERSITY
630 WEST 168TH STREET BOX 49	NEW YORK	NY	10032	135598093	501 (C)(3)	$201,250	$0	SEMAPHORIN REGULATION OF DISEASE-ASSOCIATED MICROGLIA IN ALZHEIMER'S DISEASE
COLUMBIA UNIVERSITY
630 WEST 168TH STREET BOX 49	NEW YORK	NY	10032	135598093	501 (C)(3)	$201,250	$0	NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE
DUKE UNIVERSITY SCHOOL OF MEDICINE
324 BLACKWELL STREET SUITE 900	DURHAM	NC	27701	562247203	501 (C)(3)	$204,656	$0	CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE
DUKE UNIVERSITY SCHOOL OF MEDICINE
324 BLACKWELL STREET SUITE 900	DURHAM	NC	27701	562247203	501 (C)(3)	$320,033	$0	UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES
EMORY UNIVERSITY
1599 CLIFTON ROAD NE 4TH FLOOR	ATLANTA	GA	303224250	580566256	501 (C)(3)	$201,250	$0	MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION	1599-001-1BA
GLADSTONE INSTITUTES
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501 (C)(3)	$258,573	$0	DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT)
GLADSTONE INSTITUTES
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501 (C)(3)	$201,250	$0	DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES
GLADSTONE INSTITUTES
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501 (C)(3)	$258,615	$0	DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT)
GLADSTONE INSTITUTES
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501 (C)(3)	$201,250	$0	DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODEL
HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION
PO BOX 4384	HOUSTON	TX	77210	760094743	501 (C)(3)	$201,167	$0	A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS
HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION
PO BOX 4384	HOUSTON	TX	77210	760094743	501 (C)(3)	$57,500	$0	CANCER-DERIVED EXTRACELLULAR VESICLE MICRORNAS AS SYSTEMIC MODULATORS OF ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$201,235	$0	RESTORING BRAIN COLLECTION IN NEW YORK CITY THROUGH THE MOUNT SINAI NEUROPATHOLOGY BRAIN BANK
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$150,786	$0	ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$230,000	$0	INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$80,500	$0	COMBINATORIAL ROLES OF EED AND PICALM IN MICROGLIAL CLEARANCE PATHWAYS IN ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$201,250	$0	INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$201,250	$0	INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$115,000	$0	CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE BOX 1075	NEW YORK	NY	10029	136171197	501 (C)(3)	$201,250	$0	ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE
JOHNS HOPKINS UNIVERSITY
733 N BROADWAY MRB SUITE 117	BALTIMORE	MD	21205	520595110	501 (C)(3)	$201,250	$0	A TEMPORALLY ALIGNED MULTIMODAL FRAMEWORK FOR INDIVIDUALIZED ALZHEIMER'S DISEASE RISK ASSESSMENT AND DEEP LEARNING-DRIVEN PROGNOSIS
JOHNS HOPKINS UNIVERSITY
733 N BROADWAY MRB SUITE 117	BALTIMORE	MD	21205	520595110	501 (C)(3)	$143,697	$0	BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY
JOHNS HOPKINS UNIVERSITY
733 N BROADWAY MRB SUITE 117	BALTIMORE	MD	21205	520595110	501 (C)(3)	$201,250	$0	FROM MOLECULAR HETEROGENEITY TO PREDICTIVE MEDICINE: TRANSFORMING NEURODEGENERATIVE DISEASE RESEARCH THROUGH SPATIAL MULTI-OMICS AND INTERPRETABLE AI
MARYLAND MEDICAL LEGAL FOUNDATION
900 WEST BALTIMORE STREET	BALTIMORE	MD	21223	520786068	501 (C)(3)	$57,500	$0	BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$287,500	$0	BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$4,025	$0	ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS (SUPPLEMENT)
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	RIN3 AND BIN1 INTERACTION CONNECTS ENDOSOMAL PATHOLOGY WITH AMYLOID PATHOLOGY
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	PRECISION GENE THERAPY TARGETING MICROGLIA IN ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	ENGINEERING A HUMAN REGION-SPECIFIC SYSTEM TO PROBE APOE-LINKED CELLULAR VULNERABILITY AND RESILIENCE IN ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$100,625	$0	AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$258,750	$0	EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT)
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$201,250	$0	CENTENARIAN MICROGLIA REVEAL A NEPRILYSIN-DEPENDENT MECHANISM OF RESILIENCE IN ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$230,000	$0	ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$1,955,000	$0	THE CUREALZ ALZHEIMER'S GENOME PROJECT
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$100,600	$0	ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA ST SUITE 540	BOSTON	MA	02114	041564655	501 (C)(3)	$100,625	$0	CHARACTERIZATION AND OPTIMIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$258,750	$0	ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT)
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$252,076	$0	MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$201,250	$0	IDENTIFYING SEX-AWARE X-CHROMOSOME TARGETS FOR PRECLINICAL ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$300,000	$0	UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$8,533	$0	ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (SUPPLEMENT)
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$201,250	$0	CIRCUIT DYNAMICS IN APOE4 MICE
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$201,250	$0	INTERNEURON THERAPY FOR ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$201,250	$0	DEVELOPMENT OF A FLAP-TARGETED NEUROIMMUNE PET TRACER FOR IMAGING MICROGLIA IN AD
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET	BOSTON	MA	02114	042697983	501 (C)(3)	$200,416	$0	CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMER'S DISEASE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
77 MASSACHUSETTS AVENUE	CAMBRIDGE	MA	02139	042103594	501 (C)(3)	$287,477	$0	BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
77 MASSACHUSETTS AVENUE	CAMBRIDGE	MA	02139	042103594	501 (C)(3)	$9,752	$0	DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE (SUPPLEMENT)
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	322241865	593337028	501 (C)(3)	$201,250	$0	LINKING SLEEP DYSFUNCTION TO TAU-RELATED DEGENERATION ACROSS AD VARIANTS
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	322241865	593337028	501 (C)(3)	$201,250	$0	THE MULTI-OMIC ROADMAP TO NEURONAL SENESCENCE IN ALZHEIMER'S DISEASE
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	322241865	593337028	501 (C)(3)	$230,000	$0	UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	322241865	593337028	501 (C)(3)	$201,250	$0	EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS
MAYO CLINIC JACKSONVILLE
4500 SAN PABLO ROAD	JACKSONVILLE	FL	322241865	593337028	501 (C)(3)	$201,250	$0	ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE 4 GENE ALLELE IN ANIMAL MODELS
MAYO CLINIC ROCHESTER
200 FIRST ST SW	ROCHESTER	MN	55905	416011702	501 (C)(3)	$201,250	$0	BRIDGING THE GAP: SEX-SPECIFIC DRIVERS OF SENESCENCE UNDERLYING NEURODEGENERATION
MEMORIAL SLOAN KETTERING CANCER CENTER
1275 YORK AVE	NEW YORK	NY	10065	131924236	501 (C)(3)	$201,250	$0	DEVELOPMENT AND MECHANISM OF AUTOPHAGY ACTIVATORS FOR TREATMENT OF ALZHEIMER'S DISEASE
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE
900 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	GOVERNMENT	$287,673	$0	BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE
900 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	GOVERNMENT	$80,500	$0	DYNAMIC INVESTIGATION OF LYMPHATIC PATHWAY INTERCONNECTIONS FOR CEREBROSPINAL FLUID CLEARANCE OF THE HUMAN CENTRAL NERVOUS SYSTEM IN VIVO UNDER PHYSIOLOGICAL CONDITIONS OF THE BRAIN'S BORDERS
SEATTLE NEUROSOUND SOLUTIONS
1126 38TH AVENUE EAST	SEATTLE	WA	98112	884199640		$175,000	$0	CONTINUOUS MONITORING AND ENHANCEMENT OF GLYMPHATIC FLOW IN HUMAN SLEEP
NEW YORK GENOME CENTER
101 AVENUE OF THE AMERICAS 7TH	NEW YORK	NY	10013	800631734	501 (C)(3)	$86,250	$0	CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION	FLOOR
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
550 FIRST AVE	NEW YORK	NY	10016	135562308	501 (C)(3)	$201,250	$0	MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE-ONSET ALZHEIMER'S DISEASE IN WOMEN
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
550 FIRST AVE	NEW YORK	NY	10016	135562308	501 (C)(3)	$210,962	$0	MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
550 FIRST AVE	NEW YORK	NY	10016	135562308	501 (C)(3)	$287,500	$0	NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
550 FIRST AVE	NEW YORK	NY	10016	135562308	501 (C)(3)	$80,500	$0	ASTROCYTE NETWORK STRUCTURE AND FUNCTION IN ALZHEIMER'S DISEASE
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
550 FIRST AVE	NEW YORK	NY	10016	135562308	501 (C)(3)	$201,250	$0	VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVE ABBOTT 1416	CHICAGO	IL	60611	362167817	501 (C)(3)	$201,250	$0	SEX-SPECIFIC MECHANISMS OF NEUROINFLAMMATION IN THE ALZHEIMER'S DISEASE HYPOTHALAMUS
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVE ABBOTT 1416	CHICAGO	IL	60611	362167817	501 (C)(3)	$201,250	$0	ROLE OF TAU IN PRESYNAPTIC DYSFUNCTION DURING THE CELLULAR PHASE OF ALZHEIMER'S DISEASE
NORTHWESTERN UNIVERSITY
710 N LAKE SHORE DRIVE ABBOTT 1416	CHICAGO	IL	60611	362167817	501 (C)(3)	$57,500	$0	ROLE OF ANNEXIN A6-MEDIATED MEMBRANE REPAIR IN ALZHEIMER'S PATHOLOGY
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
1033 MASSACHUSETTS AVE 3RD FLOOR	CAMBRIDGE	MA	02138	042103580	501 (C)(3)	$38,944	$0	PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA (SUPPLEMENT)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
1033 MASSACHUSETTS AVE 3RD FLOOR	CAMBRIDGE	MA	02138	042103580	501 (C)(3)	$230,000	$0	MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
1033 MASSACHUSETTS AVE 3RD FLOOR	CAMBRIDGE	MA	02138	042103580	501 (C)(3)	$80,500	$0	FBAT-EQUIVALENCE TESTING IN THE PRESENCE OF MODEL UNCERTAINTY FOR THE CURE ALZHEIMERS GENOME PROJECT
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
1033 MASSACHUSETTS AVE 3RD FLOOR	CAMBRIDGE	MA	02138	042103580	501 (C)(3)	$201,250	$0	MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$201,250	$0	DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$150,937	$0	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$201,250	$0	SON-DEPENDENT NUCLEAR SPECKLE REJUVENATION: A NOVEL PROTEOSTASIS-BASED THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$287,500	$0	BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE?
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$80,500	$0	MECHANISMS REGULATING NEUROVASCULAR FUNCTION IN ALZHEIMER'S DISEASE
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$287,500	$0	NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION
REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DRIVE MC 0934	LA JOLLA	CA	920930636	952872494	501 (C)(3)	$230,000	$0	APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME
ST JUDE CHILDREN'S RESEARCH HOSPITAL
262 DANNY THOMAS PLACE	MEMPHIS	TN	38105	620646012	501 (C)(3)	$92,000	$0	DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE
STANFORD UNIVERSITY
485 BROADWAY	REDWOOD CITY	CA	94063	941156365	501 (C)(3)	$198,253	$0	BMP LIPID METABOLISM AS A THERAPEUTIC TARGET FOR LYSOSOMAL FUNCTION AND ALZHEIMER'S DISEASE PATHOGENESIS
STANFORD UNIVERSITY
485 BROADWAY	REDWOOD CITY	CA	94063	941156365	501 (C)(3)	$198,370	$0	OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE
STANFORD UNIVERSITY
485 BROADWAY	REDWOOD CITY	CA	94063	941156365	501 (C)(3)	$287,500	$0	BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE
STATE OF MARYLAND -UNIVERSITY OF MARYLAND BALTIMORE
PO BOX 41428	BALTIMORE	MD	212036428	526002033	501 (C)(3)	$171,037	$0	EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
THE BROAD INSTITUTE INC
415 MAIN STREET	CAMBRIDGE	MA	02142	263428781	501 (C)(3)	$230,000	$0	INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS
THE MCLEAN HOSPITAL CORPORATION
115 MILL STREET	BELMONT	MA	02478	042697981	501 (C)(3)	$327,501	$0	EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
490 ILLINOIS STREET 4TH FLOOR	SAN FRANCISCO	CA	94143	943067788	501 (C)(3)	$201,250	$0	NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
490 ILLINOIS STREET 4TH FLOOR	SAN FRANCISCO	CA	94143	943067788	501 (C)(3)	$201,250	$0	PROBING THE MOLECULAR UNDERPINNINGS OF HOW G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATES PROTECTIVE RESPONSES TO ALZHEIMER'S DISEASE
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
490 ILLINOIS STREET 4TH FLOOR	SAN FRANCISCO	CA	94143	943067788	501 (C)(3)	$80,500	$0	DEFINE ADGRG1-MEDIATED PROTECTIVE MICROGLIAL RESPONSE TO TAU TANGLES IN ALZHEIMER'S DISEASE
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
490 ILLINOIS STREET 4TH FLOOR	SAN FRANCISCO	CA	94143	943067788	501 (C)(3)	$201,250	$0	ROLE OF PLATELET-DERIVED FACTORS IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
10010 NORTH TORREY PINES ROAD	LA JOLLA	CA	92037	952160097	501 (C)(3)	$201,250	$0	THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE
TRUSTEES OF TUFTS COLLEGE DBA TUFTS UNIVERSITY
80 GEORGE ST	MEDFORD	MA	02155	042103634	501 (C)(3)	$100,625	$0	ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS
UNIVERSITY OF ALABAMA AT BIRMINGHAM
801 5TH AVE SOUTH ROOM 251	BIRMINGHAM	AL	35233	636005396	501 (C)(3)	$271,375	$0	EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK
UNIVERSITY OF CALIFORNIA DAVIS
ONE SHIELDS AVENUE	DAVIS	CA	95616	943067788	501 (C)(3)	$201,250	$0	DECIPHERING PHOSPHORYLATION-DEPENDENT TAU ENVELOPE DYSFUNCTION TO PREVENT ALZHEIMER'S NEURODEGENERATION
UNIVERSITY OF CALIFORNIA DAVIS
ONE SHIELDS AVENUE	DAVIS	CA	95616	943067788	501 (C)(3)	$286,466	$0	NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION
UNIVERSITY OF CALIFORNIA IRVINE
228 ALDRICH HALL	IRVINE	CA	92697	952226406	501 (C)(3)	$287,490	$0	NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS
UNIVERSITY OF CALIFORNIA IRVINE
228 ALDRICH HALL	IRVINE	CA	92697	952226406	501 (C)(3)	$230,000	$0	ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
UNIVERSITY OF CALIFORNIA IRVINE
228 ALDRICH HALL	IRVINE	CA	92697	952226406	501 (C)(3)	$402,492	$0	PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE
UNIVERSITY OF CALIFORNIA LOS ANGELES
10920 WILSHIRE BOULEVARD SUITE 600	LOS ANGELES	CA	90024	956006143	501 (C)(3)	$191,463	$0	NOVEL AI DECODES AGING NEURONS
UNIVERSITY OF KENTUCKY
109 KINKEAD HALL	LEXINGTON	KY	405060057	616033693	501 (C)(3)	$78,090	$0	ASSESSING THE ROLE OF APOE IN GLIAL LIPID DROPLET METABOLISM AND FUNCTION
UNIVERSITY OF KENTUCKY
109 KINKEAD HALL	LEXINGTON	KY	405060057	616033693	501 (C)(3)	$200,187	$0	LOWERING MICROGLIAL LIPID BURDEN VIA PLIN2 MODULATION IN ALZHEIMER'S DISEASE
UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL
55 LAKE AVENUE NORTH	WORCESTER	MA	01655	043167352	501 (C)(3)	$200,568	$0	VENTRICULAR EPENDYMAL CELLS: A NOVEL NEURAL-IMMUNE SIGNALING AXIS DURING AGING AND NEURODEGENERATION
UNIVERSITY OF MIAMI
PO BOX 405803	ATLANTA	GA	30384	590624458	501 (C)(3)	$24,589	$0	2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE
UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET	ANN ARBOR	MI	481091287	386006309	501 (C)(3)	$398,521	$0	UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES
UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET	ANN ARBOR	MI	481091287	386006309	501 (C)(3)	$201,251	$0	MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD
UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET	ANN ARBOR	MI	481091287	386006309	501 (C)(3)	$402,500	$0	NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES
UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET	ANN ARBOR	MI	481091287	386006309	501 (C)(3)	$103,168	$0	NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY
UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREET 5TH FLOOR	PHILADELPHIA	PA	191046205	231352685	501 (C)(3)	$284,678	$0	APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY	FRANKLIN BUILDING
UNIVERSITY OF PITTSBURGH
200 S CRAIG ST SUITE 230	PITTSBURGH	PA	15260	250965591	501 (C)(3)	$100,625	$0	AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE
UNIVERSITY OF ROCHESTER
910 GENESEE STREET SUITE 200	ROCHESTER	NY	146113847	160743209	501 (C)(3)	$287,500	$0	BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE?
UNIVERSITY OF SOUTH FLORIDA
4202 E FOWLER AVE SVC 1039	TAMPA	FL	336205800	593102112	501 (C)(3)	$201,250	$0	BIN1 IN MICROGLIAL HETEROGENEITY ALONG AD PROGRESSION AND MICROGLIAL FUNCTION
UNIVERSITY OF SOUTHERN CALIFORNIA
3500 S FIGUEROA STREET SUITE 102	LOS ANGELES	CA	900898001	951642394	501 (C)(3)	$57,500	$0	NEURAL STEM CELL REJUVENATION FOR SYMPTOMATIC ALZHEIMER'S DISEASE
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 FLOYD CURL DRIVE MSC 7828	SAN ANTONIO	TX	78229	741586031	501 (C)(3)	$181,004	$0	BRIDGING MYELIN AND VASCULAR DEMENTIA: OLIGODENDROCYTE STRESS RESPONSES IN AGEING AND CEREBROVASCULAR DISEASE
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 FLOYD CURL DRIVE MSC 7828	SAN ANTONIO	TX	78229	741586031	501 (C)(3)	$201,250	$0	HOW DO MICROGLIA CONTRIBUTE TO THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE?
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 FLOYD CURL DRIVE MSC 7828	SAN ANTONIO	TX	78229	741586031	501 (C)(3)	$201,250	$0	DIGITAL NEUROPATHOLOGY INFRASTRUCTURE FOR PRECISION MEDICINE IN SOUTH TEXAS HISPANIC AD/ADRD POPULATIONS
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 FLOYD CURL DRIVE MSC 7828	SAN ANTONIO	TX	78229	741586031	501 (C)(3)	$201,250	$0	COGNITIVELY HEALTHY NONAGENARIANS IN THE CROSS COHORT COLLABORATION (CCC)
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BLVD	DALLAS	TX	75390	756002868	501 (C)(3)	$230,000	$0	ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
UNIVERSITY OF VIRGINIA
1001 N EMMETT ST	CHARLOTTESVILLE	VA	229044195	546001796	501 (C)(3)	$201,250	$0	MICROGLIAL MITOCHONDRIAL DYSFUNCTION AND TAU TOXICITY IN ALZHEIMER'S DISEASE
UNIVERSITY OF VIRGINIA
1001 N EMMETT ST	CHARLOTTESVILLE	VA	229044195	546001796	501 (C)(3)	$201,250	$0	IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL
UNIVERSITY OF VIRGINIA
1001 N EMMETT ST	CHARLOTTESVILLE	VA	229044195	546001796	501 (C)(3)	$258,750	$0	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT)
UNIVERSITY OF VIRGINIA
1001 N EMMETT ST	CHARLOTTESVILLE	VA	229044195	546001796	501 (C)(3)	$201,250	$0	ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD
UNIVERSITY OF VIRGINIA
1001 N EMMETT ST	CHARLOTTESVILLE	VA	229044195	546001796	501 (C)(3)	$50,312	$0	THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION
UNIVERSITY OF WASHINGTON
4300 ROOSEVELT WAY NE BOX 354965	SEATTLE	WA	98105	916001537	501 (C)(3)	$200,043	$0	ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDO-LYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	SLEEP REINFORCES HOMEOSTATIC SET-POINTS IN NEURAL ACTIVITY AND MITIGATES NEURODEGENERATIVE DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$345,000	$0	APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$345,000	$0	BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$182,921	$0	MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$200,530	$0	MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$77,709	$0	SUPPRESSING NEUROINFLAMMATION WITH A TARGETED PROTEIN DEGRADATION STRATEGY IN A TAUOPATHY MOUSE MODEL
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$80,500	$0	SLEEP AUGMENTATION REINFORCES NEURAL COMPUTATION, ENHANCES COGNITION, AND MITIGATES NEURODEGENERATIVE DISEASE SYMPTOMS
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	ANTIVIRAL CYTOKINE SIGNALING PROMOTES NEURODEGENERATION IN ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$345,000	$0	BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,212	$0	NEUROPROTECTIVE T CELL-BASED THERAPY FOR ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$124,653	$0	CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$199,281	$0	CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER DISEASE PATHOGENESIS
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$287,500	$0	BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD)
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$98,083	$0	NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$287,499	$0	BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRIVE	ST LOUIS	MO	63130	430653611	501 (C)(3)	$201,250	$0	THE JEFFREY L. MORBY PRIZE
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	100654805	136094042	501 (C)(3)	$80,500	$0	MICROGLIAL-ASTROCYTIC MECHANISMS OF APOE3 CHRISTCHURCH-MEDIATED RESILIENCE TO TAUOPATHY
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	100654805	136094042	501 (C)(3)	$402,500	$0	SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	100654805	136094042	501 (C)(3)	$200,532	$0	HYPERTENSION, TAU AND NEURODEGENERATION
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	100654805	136094042	501 (C)(3)	$201,250	$0	A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	100654805	136094042	501 (C)(3)	$258,750	$0	A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT)

Field	Value	IRS element (for citing)
Total501c3 Org	54	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (9 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
MARGARET E SMITH
CEO & DIRECTOR	$436,310	$0	$65,250	$0	$0	$0	$10,500	$0	$19,119	$0	$531,179	$0	$0	$0
KATHARINE HERMAN
EVP DEVELOPMENT	$372,022	$0	$86,500	$0	$0	$0	$10,500	$0	$20,535	$0	$489,557	$0	$0	$0
BARBARA CHAMBERS
EVP MARKETING & COMM.	$283,531	$0	$19,500	$0	$0	$0	$9,511	$0	$14,967	$0	$327,509	$0	$0	$0
LISA RAND
VP MARKETING & COMM.	$208,091	$0	$9,000	$0	$0	$0	$6,821	$0	$12,673	$0	$236,585	$0	$0	$0
DANIEL HARPER
VP DEVELOPMENT	$206,418	$0	$14,500	$0	$0	$0	$6,731	$0	$7,630	$0	$235,279	$0	$0	$0
JOSEPHINE ANTONELLIS
CFO	$204,692	$0	$20,500	$0	$0	$0	$6,763	$0	$1,239	$0	$233,194	$0	$0	$0
JOHN SLATTERY
SVP, PHILANTHROPIC PARTNERSHIPS	$204,048	$0	$9,500	$0	$0	$0	$6,502	$0	$960	$0	$221,010	$0	$0	$0
MAHUA DASGUPTA
SR. PHILANTROPIC ADVISOR	$181,723	$0	$12,000	$0	$0	$0	$6,237	$0	$20,517	$0	$220,477	$0	$0	$0
THIDAPHORN SENGSAVANH
DIRECTOR OF DEVELOPMENT OPERATIONS	$163,396	$0	$7,500	$0	$0	$0	$5,403	$0	$20,279	$0	$196,578	$0	$0	$0

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PROPER VILLAINS LLC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Relationship Description	A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE	RelationshipDescriptionTxt
Transaction	$130,663	TransactionAmt
Transaction	CREATIVE AND PRODUCTION SERVICES	TransactionDesc
Sharing Of Revenues	0	SharingOfRevenuesInd

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	92	ContributionCnt
Noncash Contributions Rpt F990	$5,646,939	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	AUCTION ITEMS	Desc
Contribution	10	ContributionCnt
Noncash Contributions Rpt F990	$28,302	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (1)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	Yes (1)	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 32B:	FormAndLineReferenceDesc
Explanation	WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH JP MORGAN AND BANK OF NEW YORK/MELLON.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS.
FORM 990, PART VI, SECTION B, LINE 12C	EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION.
FORM 990, PART VI, SECTION B, LINE 15	COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES.
FORM 990, PART VI, SECTION C, LINE 19	THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.
FORM 990, PART XII, LINE 2C	THE ORGANIZATION DID NOT CHANGE EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.